We subsequently validated our findings of transcriptional adaption mechanisms by comparing public gene expression array data of HER2-amplified breast cancer patients undergoing neoadjuvant treatment with the monoclonal antibody trastuzumab33. The gene discussed is ERBB2; the disease is breast cancer.